28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
These findings support evidence of genetic control of brain volume even in adults, particularly of hippocampal and neocortical volume and of cortical volumetric reductions being familial, but do not support measures of subcortical volumes per se as representing intermediate biologic phenotypes. 4 key findings →
Participants: 169 Evidence: low
Full summary, score breakdown and related studies → Original source
Exercise training is an effective means for promoting white matter and hippocampal recovery and improving reaction time in children treated with cranial radiation for brain tumors. 3 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
In 3T MRI visually inspected by experts, quantification of hippocampal volume and signal can increase the detection of hippocampal sclerosis in 28% of patients with mesial temporal lobe epilepsy. 1 key finding →
Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source
Controversy persists regarding whether Alzheimer's disease (AD) is a distinct entity or instead exists on a continuum with nondemented aging. 5 key findings →
Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic exposure to increased glucocorticoid concentrations appears to lower the threshold for hippocampal neuronal degeneration in the old rat. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Major Depressive Disorder (MDD) is a common psychiatric disorder for which available medications are often not effective. 4 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Several patient characteristics were significantly associated with colonic preparation quality independent of preparation type, compliance with preparation instructions, and procedure starting time. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a devastating disease and global health challenge that is highly prevalent worldwide. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
This study provides partial validation of specific clinical criteria for apathy in Alzheimer's disease. 2 key findings →
Participants: 319 Evidence: low
Full summary, score breakdown and related studies → Original source
Design review and abstraction of medical records and computerized data bases from 5986 members, aged 65 years and older, of a large health maintenance organization in northern California. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Progressive cerebrovascular atherosclerosis and consecutive stroke are among the most common causes of dementia. 1 key finding →
Participants: 186 Evidence: low
Full summary, score breakdown and related studies → Original source
The prospective association between adiposity and dementia differs depending on the anthropometric measure used, and is modified by age. 2 key findings →
Participants: 893 Evidence: low
Full summary, score breakdown and related studies → Original source
A diffusion prepared 3D GRASE pCASL sequence with TGV regularized SPA modeling was proposed to measure BBB water permeability noninvasively with good reproducibility. k w may serve as an imaging marker of cerebral SVD and associated cognitive impairment. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Including plasma p-tau217/np-tau217 along with Aβ42/Aβ40 in predictive algorithms may streamline screening preclinical individuals into anti-amyloid clinical trials. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
IR among asymptomatic APOEɛ4 carriers was associated with higher P-Tau181 and T-Tau in late-middle age. 5 key findings →
Participants: 113 Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid plaques and tau tangles are the hallmark pathologic features of Alzheimer's disease (AD). 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Drug development continues robustly at all phases despite setbacks in several programs in the recent past. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Mutations in the beta-amyloid precursor protein are strongly associated with some cases of familial Alzheimer's disease. 3 key findings →
Design: cross-sectional Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Multiple biological pathways are altered and could be targeted very early in the Alzheimer's continuum. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results demonstrate that novel AD biomarker candidates are identified and confirmed by proteomic studies of brain tissue and biofluids, providing a rich resource for large-scale biomarker validation for the AD community. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The relationship between amyloid-β (Aβ) species and tau pathology in Alzheimer's disease (AD) is not fully understood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Familial Alzheimer's disease (fAD) mutations alter amyloid precursor protein (APP) cleavage by γ-secretase, increasing the proportion of longer amyloidogenic amyloid-β (Aβ) peptides. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid precursor protein (APP) mutations associated with familial Alzheimer's disease (AD) usually lead to increases in amyloid β-protein (Aβ) levels or aggregation. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →